Search

Displaying results 6711 - 6720 of 7399 in total
  1. Drug

    TAK-611

    go.drugbank.com/drugs/DB17644
    Investigational

    First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.

  2. Drug

    Benzoylecgonine

    go.drugbank.com/drugs/DB01515
    ExperimentalIllicit

    It is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. It is excreted in the urine of cocaine users after processing in the liver.

    Synonyms: O-benzoylecgonine, O-benzoyl-(-)-ecgonine
  3. Drug

    Zolazepam

    go.drugbank.com/drugs/DB11555
    ExperimentalVet approved

    It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.

  4. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.

    Synonyms: N-Desmethylclozapine
  5. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.

  6. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron is under investigation in clinical trial NCT05579977 (Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People

  7. Drug

    Fosinoprilat

    go.drugbank.com/drugs/DB14207
    Experimental

    Fosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.

  8. Drug

    AG0302-COVID19

    go.drugbank.com/drugs/DB16435
    Investigational

    Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].

  9. Drug

    GLP-1 (7-36) amide

    go.drugbank.com/drugs/DB19258
    Investigational

    GLP-1 (7-36) amide is under investigation in clinical trial NCT01185119 (Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET).

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]